ImmunityBio's (IBRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX - Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $30.00 price target on the stock.

IBRX has been the topic of a number of other research reports. Piper Sandler upgraded shares of ImmunityBio from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $4.25 to $5.00 in a research report on Tuesday, May 20th. HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of ImmunityBio in a research report on Wednesday, June 4th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $12.25.

ImmunityBio Stock Performance

IBRX traded up $0.10 on Tuesday, hitting $2.89. 4,774,237 shares of the company were exchanged, compared to its average volume of 6,230,736. The business's fifty day moving average is $2.70 and its 200 day moving average is $2.83. ImmunityBio has a fifty-two week low of $1.83 and a fifty-two week high of $7.48. The firm has a market capitalization of $2.55 billion, a P/E ratio of -4.97 and a beta of 0.08.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $16.52 million during the quarter, compared to analysts' expectations of $17.50 million. Analysts forecast that ImmunityBio will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On ImmunityBio

Large investors have recently added to or reduced their stakes in the company. Thrive Wealth Management LLC acquired a new stake in ImmunityBio during the 1st quarter valued at $30,000. Slow Capital Inc. acquired a new stake in ImmunityBio during the 1st quarter valued at $30,000. Compound Planning Inc. acquired a new stake in ImmunityBio during the 1st quarter valued at $30,000. Xponance Inc. acquired a new stake in ImmunityBio during the 1st quarter valued at $33,000. Finally, Humankind Investments LLC acquired a new stake in ImmunityBio during the 1st quarter valued at $34,000. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.